Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:MAP2K2-ZDHHC12 (FusionGDB2 ID:50942)

Fusion Gene Summary for MAP2K2-ZDHHC12

Fusion gene summary

Fusion gene information	Fusion gene name: MAP2K2-ZDHHC12
	Fusion gene ID: 50942
		Hgene	Tgene
	Gene symbol	MAP2K2	ZDHHC12
	Gene ID	5605	84885
	Gene name	mitogen-activated protein kinase kinase 2	zinc finger DHHC-type palmitoyltransferase 12
	Synonyms	CFC4\|MAPKK2\|MEK2\|MKK2\|PRKMK2	DHHC-12\|ZNF400
	Cytomap	19p13.3	9q34.11
	Type of gene	protein-coding	protein-coding
	Description	dual specificity mitogen-activated protein kinase kinase 2ERK activator kinase 2MAP kinase kinase 2MAPK/ERK kinase 2mitogen-activated protein kinase kinase 2, p45	probable palmitoyltransferase ZDHHC12zinc finger DHHC domain-containing protein 12zinc finger DHHC-type containing 12zinc finger protein 400
	Modification date	20200327	20200313
	UniProtAcc	P36507	.
	Ensembl transtripts involved in fusion gene	ENST00000262948, ENST00000394867, ENST00000599345,	ENST00000372663, ENST00000372672, ENST00000372667, ENST00000467312,
Fusion gene scores	* DoF score	10 X 6 X 6=360	2 X 2 X 2=8
	# samples	10	2
	** MAII score	log2(10/360*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(2/8*10)=1.32192809488736
Context	PubMed: MAP2K2 [Title/Abstract] AND ZDHHC12 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	MAP2K2(4097277)-ZDHHC12(131484853), # samples:1
Anticipated loss of major functional domain due to fusion event.	MAP2K2-ZDHHC12 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. MAP2K2-ZDHHC12 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. MAP2K2-ZDHHC12 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. MAP2K2-ZDHHC12 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MAP2K2	GO:0036289	peptidyl-serine autophosphorylation	8388392
Hgene	MAP2K2	GO:0071902	positive regulation of protein serine/threonine kinase activity	8388392
Tgene	ZDHHC12	GO:0018345	protein palmitoylation	23034182

Fusion gene breakpoints across MAP2K2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ZDHHC12 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	LIHC	TCGA-G3-A7M7-01A	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-

Top

Fusion Gene ORF analysis for MAP2K2-ZDHHC12

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
Frame-shift	ENST00000262948	ENST00000372663	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
Frame-shift	ENST00000262948	ENST00000372672	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
Frame-shift	ENST00000262948	ENST00000372667	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
5CDS-5UTR	ENST00000262948	ENST00000467312	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
In-frame	ENST00000394867	ENST00000372663	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
In-frame	ENST00000394867	ENST00000372672	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
In-frame	ENST00000394867	ENST00000372667	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
5CDS-5UTR	ENST00000394867	ENST00000467312	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
intron-3CDS	ENST00000599345	ENST00000372663	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
intron-3CDS	ENST00000599345	ENST00000372672	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
intron-3CDS	ENST00000599345	ENST00000372667	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-
intron-5UTR	ENST00000599345	ENST00000467312	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000394867	MAP2K2	chr19	4097277	-	ENST00000372663	ZDHHC12	chr9	131484853	-	2003	987	9	1103	364
ENST00000394867	MAP2K2	chr19	4097277	-	ENST00000372672	ZDHHC12	chr9	131484853	-	1847	987	9	1103	364
ENST00000394867	MAP2K2	chr19	4097277	-	ENST00000372667	ZDHHC12	chr9	131484853	-	2002	987	9	1103	364

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000394867	ENST00000372663	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-	0.04473445	0.9552655
ENST00000394867	ENST00000372672	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-	0.03739042	0.9626095
ENST00000394867	ENST00000372667	MAP2K2	chr19	4097277	-	ZDHHC12	chr9	131484853	-	0.04454326	0.95545673

Top

Fusion Genomic Features for MAP2K2-ZDHHC12

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for MAP2K2-ZDHHC12

Go to
FGviewer for the breakpoints of chr19:4097277-chr9:131484853
.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
MAP2K2 P36507	.
FUNCTION: Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). {ECO:0000250\|UniProtKB:Q63932, ECO:0000269\|PubMed:29433126}.	FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MAP2K2

chr19:4097277

chr9:131484853

ENST00000262948

266_315

328.0

401.0

Compositional bias

Note=Pro-rich

Hgene

MAP2K2

chr19:4097277

chr9:131484853

ENST00000262948

78_86

328.0

401.0

Nucleotide binding

ATP

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

97_147

33.333333333333336

268.0

Domain

DHHC

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

162_178

33.333333333333336

268.0

Topological domain

Lumenal

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

200_267

33.333333333333336

268.0

Topological domain

Cytoplasmic

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

31_43

33.333333333333336

268.0

Topological domain

Lumenal

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

65_140

33.333333333333336

268.0

Topological domain

Cytoplasmic

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

141_161

33.333333333333336

268.0

Transmembrane

Helical

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

179_199

33.333333333333336

268.0

Transmembrane

Helical

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

44_64

33.333333333333336

268.0

Transmembrane

Helical

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MAP2K2

chr19:4097277

chr9:131484853

ENST00000262948

72_369

328.0

401.0

Domain

Protein kinase

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

1_9

33.333333333333336

268.0

Topological domain

Cytoplasmic

Tgene

ZDHHC12

chr19:4097277

chr9:131484853

ENST00000372663

10_30

33.333333333333336

268.0

Transmembrane

Helical

Top

Fusion Gene Sequence for MAP2K2-ZDHHC12

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>In-frame_ENST00000394867_ENST00000372663_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(transcript)=2003nt_BP=987nt
GGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGGCCCATCCCCTACCAGCGAGGGCGCC
TCCGAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACC
CAGAAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTC
CAGCACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTG
CAGGTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACAC
ATGGACGGCGGCTCCCTGGACCAGGTGCTGAAAGAGGCCAAGAGGATTCCCGAGGAGATCCTGGGGAAAGTCAGCATCGCGGTTCTCCGG
GGCTTGGCGTACCTCCGAGAGAAGCACCAGATCATGCACCGAGATGTGAAGCCCTCCAACATCCTCGTGAACTCTAGAGGGGAGATCAAG
CTGTGTGACTTCGGGGTGAGCGGCCAGCTCATCGACTCCATGGCCAACTCCTTCGTGGGCACGCGCTCCTACATGGCTCCGGAGCGGTTG
CAGGGCACACATTACTCGGTGCAGTCGGACATCTGGAGCATGGGCCTGTCCCTGGTGGAGCTGGCCGTCGGAAGGTACCCCATCCCCCCG
CCCGACGCCAAAGAGCTGGAGGCCATCTTTGGCCGGCCCGTGGTCGACGGGGAAGAAGGAGAGCCTCACAGCATCTCGCCTCGGCCGAGG
CCCCCCGGGCGCCCCGTCAGCGGTCACGGGATGGATAGCCGGCCTGCCATGGCCATCTTTGAACTCCTGGACTATATTGTGAACGAGAGC
TGCGGCAATGGGAGGAGCAGGGGGAGCTGCTCCTGCCCCTCACCTTCCTGCTCCTGGTGCTGGGCTCCCTGCTGCTCTACCTCGCTGTGT
CACTCATGGACCCTGGCTACGTGAATGTGCAGCCCCAGCCTCAGGAGGAGCTCAAAGAGGAGCAGACAGCCATGGTTCCTCCAGCCATCC
CTCTTCGGCGCTGCAGATACTGCCTGGTGCTGCAGCCCCTGAGGGCTCGGCACTGCCGTGAGTGCCGCCGTTGCGTCCGCCGCTACGACC
ACCACTGCCCCTGGATGGAGAACTGTGTGGGAGAGCGCAACCACCCACTCTTTGTGGTCTACCTGGCGCTGCAGCTGGTGGTGCTTCTGT
GGGGCCTGTACCTGGCATGGTCAGGCCTCCGGTTCTTCCAGCCCTGGGGTCAGTGGTTGCGGTCCAGCGGGCTCCTGTTCGCCACCTTCC
TGCTGCTGTCCCTCTTCTCGTTGGTGGCCAGCCTGCTCCTCGTCTCGCACCTCTACCTGGTGGCCAGCAACACCACCACCTGGGAATTCA
TCTCCTCACACCGCATCGCCTATCTCCGCCAGCGCCCCAGCAACCCCTTCGACCGAGGCCTGACCCGCAACCTGGCCCACTTCTTCTGTG
GATGGCCCTCAGGGTCCTGGGAGACCCTCTGGGCTGAGGAGGAGGAAGAGGGCAGCAGCCCAGCTGTTTAGGGTTGCTGGAGGCCGGGCT
ACCGTCTTGTGCCTGAAAACCACGGGGCCTGTCCCCAGCTGGGGTGAGCGCTCAGAGGGCCTGGGGCCCTCACTCCTGCCCACGCCTCCC
AGACCCCAGAACGGAGCTTCAAGTCAGACAGATCCCTGCCTTGGTGGGCAGTTCTGCCTTCCAAGGAAGAAGGGGAAGAAAAGGACCTGT
GGGTGGCTCAGGCCCAAGCAGACCCCGGGCTCCACCCCAGCCCCGCCCAGGCTGCTGCCAGTGCACACTTTTACAAATTTAATATAAAGC

>In-frame_ENST00000394867_ENST00000372663_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(amino acids)=364AA_start in transcript=9_stop in transcript=1103
MRRQPSSGLGSGSGSLASGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHR
PSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLA
YLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDA
KELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNESCGNGRSRGSCSCPSPSCSWCWAPCCSTSLCHSW

--------------------------------------------------------------
>In-frame_ENST00000394867_ENST00000372672_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(transcript)=1847nt_BP=987nt
GGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGGCCCATCCCCTACCAGCGAGGGCGCC
TCCGAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACC
CAGAAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTC
CAGCACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTG
CAGGTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACAC
ATGGACGGCGGCTCCCTGGACCAGGTGCTGAAAGAGGCCAAGAGGATTCCCGAGGAGATCCTGGGGAAAGTCAGCATCGCGGTTCTCCGG
GGCTTGGCGTACCTCCGAGAGAAGCACCAGATCATGCACCGAGATGTGAAGCCCTCCAACATCCTCGTGAACTCTAGAGGGGAGATCAAG
CTGTGTGACTTCGGGGTGAGCGGCCAGCTCATCGACTCCATGGCCAACTCCTTCGTGGGCACGCGCTCCTACATGGCTCCGGAGCGGTTG
CAGGGCACACATTACTCGGTGCAGTCGGACATCTGGAGCATGGGCCTGTCCCTGGTGGAGCTGGCCGTCGGAAGGTACCCCATCCCCCCG
CCCGACGCCAAAGAGCTGGAGGCCATCTTTGGCCGGCCCGTGGTCGACGGGGAAGAAGGAGAGCCTCACAGCATCTCGCCTCGGCCGAGG
CCCCCCGGGCGCCCCGTCAGCGGTCACGGGATGGATAGCCGGCCTGCCATGGCCATCTTTGAACTCCTGGACTATATTGTGAACGAGAGC
TGCGGCAATGGGAGGAGCAGGGGGAGCTGCTCCTGCCCCTCACCTTCCTGCTCCTGGTGCTGGGCTCCCTGCTGCTCTACCTCGCTGTGT
CACTCATGGACCCTGGCTACGTGAATGTGCAGCCCCAGCCTCAGGAGGAGCTCAAAGAGGAGCAGACAGCCATGGTTCCTCCAGCCATCC
CTCTTCGGCGCTGCAGATACTGCCTGGTGCTGCAGCCCCTGAGGGCTCGGCACTGCCGTGAGTGCCGCCGTTGCGTCCGCCGCTACGACC
ACCACTGCCCCTGGATGGAGAACTGTGTGGGAGAGCGCAACCACCCACTCTTTGTGGTCTACCTGGCGCTGCAGCTGGTGGTGCTTCTGT
GGGGCCTGTACCTGGCATGGTCAGGCCTCCGGTTCTTCCAGCCCTGGGGTCAGTGGTTGCGGTCCAGCGGGCTCCTGTTCGCCACCTTCC
TGCTGCTGGCCCACTTCTTCTGTGGATGGCCCTCAGGGTCCTGGGAGACCCTCTGGGCTGAGGAGGAGGAAGAGGGCAGCAGCCCAGCTG
TTTAGGGTTGCTGGAGGCCGGGCTACCGTCTTGTGCCTGAAAACCACGGGGCCTGTCCCCAGCTGGGGTGAGCGCTCAGAGGGCCTGGGG
CCCTCACTCCTGCCCACGCCTCCCAGACCCCAGAACGGAGCTTCAAGTCAGACAGATCCCTGCCTTGGTGGGCAGTTCTGCCTTCCAAGG
AAGAAGGGGAAGAAAAGGACCTGTGGGTGGCTCAGGCCCAAGCAGACCCCGGGCTCCACCCCAGCCCCGCCCAGGCTGCTGCCAGTGCAC

>In-frame_ENST00000394867_ENST00000372672_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(amino acids)=364AA_start in transcript=9_stop in transcript=1103
MRRQPSSGLGSGSGSLASGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHR
PSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLA
YLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDA
KELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNESCGNGRSRGSCSCPSPSCSWCWAPCCSTSLCHSW

--------------------------------------------------------------
>In-frame_ENST00000394867_ENST00000372667_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(transcript)=2002nt_BP=987nt
GGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGGCCCATCCCCTACCAGCGAGGGCGCC
TCCGAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACC
CAGAAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTC
CAGCACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTG
CAGGTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACAC
ATGGACGGCGGCTCCCTGGACCAGGTGCTGAAAGAGGCCAAGAGGATTCCCGAGGAGATCCTGGGGAAAGTCAGCATCGCGGTTCTCCGG
GGCTTGGCGTACCTCCGAGAGAAGCACCAGATCATGCACCGAGATGTGAAGCCCTCCAACATCCTCGTGAACTCTAGAGGGGAGATCAAG
CTGTGTGACTTCGGGGTGAGCGGCCAGCTCATCGACTCCATGGCCAACTCCTTCGTGGGCACGCGCTCCTACATGGCTCCGGAGCGGTTG
CAGGGCACACATTACTCGGTGCAGTCGGACATCTGGAGCATGGGCCTGTCCCTGGTGGAGCTGGCCGTCGGAAGGTACCCCATCCCCCCG
CCCGACGCCAAAGAGCTGGAGGCCATCTTTGGCCGGCCCGTGGTCGACGGGGAAGAAGGAGAGCCTCACAGCATCTCGCCTCGGCCGAGG
CCCCCCGGGCGCCCCGTCAGCGGTCACGGGATGGATAGCCGGCCTGCCATGGCCATCTTTGAACTCCTGGACTATATTGTGAACGAGAGC
TGCGGCAATGGGAGGAGCAGGGGGAGCTGCTCCTGCCCCTCACCTTCCTGCTCCTGGTGCTGGGCTCCCTGCTGCTCTACCTCGCTGTGT
CACTCATGGACCCTGGCTACGTGAATGTGCAGCCCCAGCCTCAGGAGGAGCTCAAAGAGGAGCAGACAGCCATGGTTCCTCCAGCCATCC
CTCTTCGGCGCTGCAGATACTGCCTGGTGCTGCAGCCCCTGAGGGCTCGGCACTGCCGTGAGTGCCGCCGTTGCGTCCGCCGCTACGACC
ACCACTGCCCCTGGATGGAGAACTGTGTGGGAGAGCGCAACCACCCACTCTTTGTGGTCTACCTGGCGCTGCAGCTGGTGGTGCTTCTGT
GGGGCCTGTACCTGGCATGGTCAGGCCTCCGGTTCTTCCAGCCCTGGGGTCAGTGGTTGCGGTCCAGCGGGCTCCTGTTCGCCACCTTCC
TGCTGCTGTCCCTCTTCTCGTTGGTGGCCAGCCTGCTCCTCGTCTCGCACCTCTACCTGGTGGCCAGCAACACCACCACCTGGGAATTCA
TCTCCTCACACCGCATCGCCTATCTCCGCCAGCGCCCCAGCAACCCCTTCGACCGAGGCCTGACCCGCAACCTGGCCCACTTCTTCTGTG
GATGGCCCTCAGGGTCCTGGGAGACCCTCTGGGCTGAGGAGGAGGAAGAGGGCAGCAGCCCAGCTGTTTAGGGTTGCTGGAGGCCGGGCT
ACCGTCTTGTGCCTGAAAACCACGGGGCCTGTCCCCAGCTGGGGTGAGCGCTCAGAGGGCCTGGGGCCCTCACTCCTGCCCACGCCTCCC
AGACCCCAGAACGGAGCTTCAAGTCAGACAGATCCCTGCCTTGGTGGGCAGTTCTGCCTTCCAAGGAAGAAGGGGAAGAAAAGGACCTGT
GGGTGGCTCAGGCCCAAGCAGACCCCGGGCTCCACCCCAGCCCCGCCCAGGCTGCTGCCAGTGCACACTTTTACAAATTTAATATAAAGC

>In-frame_ENST00000394867_ENST00000372667_TCGA-G3-A7M7-01A_MAP2K2_chr19_4097277_-_ZDHHC12_chr9_131484853_length(amino acids)=364AA_start in transcript=9_stop in transcript=1103
MRRQPSSGLGSGSGSLASGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHR
PSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLA
YLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDA
KELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNESCGNGRSRGSCSCPSPSCSWCWAPCCSTSLCHSW

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for MAP2K2-ZDHHC12

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for MAP2K2-ZDHHC12

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner	Gene	UniProtAcc	DrugBank ID	Drug name	Drug activity	Drug type	Drug status
Hgene	MAP2K2	P36507	DB06616	Bosutinib	Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB06616	Bosutinib	Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB06616	Bosutinib	Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB06616	Bosutinib	Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB08911	Trametinib	Antagonist\|Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB08911	Trametinib	Antagonist\|Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB08911	Trametinib	Antagonist\|Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB08911	Trametinib	Antagonist\|Inhibitor	Small molecule	Approved
Hgene	MAP2K2	P36507	DB11689	Selumetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11689	Selumetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11689	Selumetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11689	Selumetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11967	Binimetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11967	Binimetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11967	Binimetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB11967	Binimetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	MAP2K2	P36507	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational

Top

Related Diseases for MAP2K2-ZDHHC12

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	MAP2K2	C1275081	Cardio-facio-cutaneous syndrome	13	CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
Hgene	MAP2K2	C3809007	CARDIOFACIOCUTANEOUS SYNDROME 4	7	GENOMICS_ENGLAND;UNIPROT
Hgene	MAP2K2	C0028326	Noonan Syndrome	4	CLINGEN;CTD_human
Hgene	MAP2K2	C0010606	Adenoid Cystic Carcinoma	1	CTD_human
Hgene	MAP2K2	C0025202	melanoma	1	CGI;CTD_human
Hgene	MAP2K2	C0041409	Turner Syndrome, Male	1	CTD_human
Hgene	MAP2K2	C0553586	Cafe-au-lait macules with pulmonary stenosis	1	ORPHANET
Hgene	MAP2K2	C0587248	Costello syndrome (disorder)	1	CLINGEN;CTD_human
Hgene	MAP2K2	C1527404	Female Pseudo-Turner Syndrome	1	CTD_human
Hgene	MAP2K2	C2931482	Neurofibromatosis-Noonan syndrome	1	ORPHANET
Hgene	MAP2K2	C4551602	Noonan Syndrome 1	1	CTD_human